首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1964篇
  免费   173篇
  国内免费   276篇
  2024年   1篇
  2023年   32篇
  2022年   25篇
  2021年   61篇
  2020年   89篇
  2019年   102篇
  2018年   57篇
  2017年   58篇
  2016年   83篇
  2015年   126篇
  2014年   143篇
  2013年   166篇
  2012年   109篇
  2011年   154篇
  2010年   124篇
  2009年   116篇
  2008年   126篇
  2007年   120篇
  2006年   122篇
  2005年   87篇
  2004年   79篇
  2003年   73篇
  2002年   52篇
  2001年   39篇
  2000年   35篇
  1999年   29篇
  1998年   37篇
  1997年   17篇
  1996年   10篇
  1995年   16篇
  1994年   15篇
  1993年   8篇
  1992年   17篇
  1991年   12篇
  1990年   5篇
  1989年   12篇
  1988年   3篇
  1987年   10篇
  1986年   7篇
  1985年   3篇
  1984年   5篇
  1983年   4篇
  1982年   8篇
  1981年   3篇
  1980年   2篇
  1979年   5篇
  1978年   4篇
  1976年   2篇
排序方式: 共有2413条查询结果,搜索用时 27 毫秒
91.
目的:克隆38kD、ESAT-6、CFP10和MPT64等4种结核分枝杆菌抗原基因,利用大肠杆菌表达系统分别表达重组蛋白,纯化并初步评价其抗原性。方法:通过PCR方法从结核分枝杆菌H37Rv株基因组中扩增38kD、ESAT-6、CFP10和MPT64抗原的基因,连接入pBVIL1表达载体,在大肠杆菌HB101株中进行表达,以间接ELISA方法初步评价其抗原性。结果:获得了结核分枝杆菌抗原38kD、ESAT-6、CFP10和MPT64的基因,并在大肠杆菌中进行了高效表达,初步验证所纯化获得的抗原具有良好的抗原性。结论:pBVIL1表达载体可以高效表达多种结核分枝杆菌抗原,38kD、ESAT-6和CFP10抗原均可作为结核病血清学诊断的候选抗原。  相似文献   
92.
目的 研究抗酸染色结核分枝杆菌(简称结核杆菌)阳性痰涂片标本直接用于耐药性检测的方法。方法 对18株临床分离培养的结核杆菌用利福平进行药敏试验。分别提取菌株DNA和与之对应的痰涂片标本的菌体DNA,用聚合酶链反应(PcR)扩增ropB基因后进行固相杂交和核酸测序检测结核杆菌的耐药性。结果 18株结核杆菌中有12株对利福平耐药。经PCR扩增的ropB片段与探针杂交后,敏感菌株未发现rpoB基因的突变,自耐药菌株提取的DNA中rpoB突变体的检出率为100%(12/12),痰涂片提取DNA的检出率为91.7%(11/12)。所有耐药菌株DNA与痰涂片DNA核酸测序结果相吻合,都有rpoB基因核心区域碱基突变。结论 抗酸染色痰涂片阳性标本可直接用于检测结核杆菌利福平耐药基因rpoB突变体,是一种值得临床实验室推广使用的耐药菌诊断方法。  相似文献   
93.
94.
为探讨铜(Cu)胁迫条件下土壤微生物对海州香薷(Elsholtzia splendens)光合生理和叶绿素荧光参数的影响,实验设置添加Cu(Cu胁迫)、接种土壤微生物、添加Cu与接种土壤微生物等3个处理,以不添加Cu与不接种土壤微生物为对照(CK)。结果表明:接种土壤微生物处理的植株相对叶绿素含量、净光合速率(Pn)、水分利用效率(WUE)均显著高于CK;且对初始荧光(Fo)和最大光化学效率(Fv/Fm)均有显著性影响。与CK相比,添加Cu降低了海州香薷的Pn和气孔导度(Gs),但胞间CO2浓度(Ci)的变化与Pn相反,表明其对光合作用的影响主要是非气孔限制因素。添加Cu的植株相对叶绿素含量显著下降,但Cu胁迫下接种土壤微生物提高了植株相对叶绿素含量,差异显著。在Cu胁迫条件下,接种土壤微生物的植株具有较高的Fv/Fm及较低的Fo,显著提高了海州香薷的WUEPnGs。说明接种土壤微生物可通过提高相对叶绿素含量、改善叶绿素荧光和光合作用来减轻Cu胁迫对海州香薷植株造成的伤害,从而提高海州香薷耐受Cu胁迫的能力。  相似文献   
95.
Here, we report the NMR solution structures of Mycobacterium tuberculosis (M. tuberculosis) thioredoxin C in both oxidized and reduced states, with discussion of structural changes that occur in going between redox states. The NMR solution structure of the oxidized TrxC corresponds closely to that of the crystal structure, except in the C‐terminal region. It appears that crystal packing effects have caused an artifactual shift in the α4 helix in the previously reported crystal structure, compared with the solution structure. On the basis of these TrxC structures, chemical shift mapping, a previously reported crystal structure of the M. tuberculosis thioredoxin reductase (not bound to a Trx) and structures for intermediates in the E. coli thioredoxin catalytic cycle, we have modeled the complete M. tuberculosis thioredoxin system for the various steps in the catalytic cycle. These structures and models reveal pockets at the TrxR/TrxC interface in various steps in the catalytic cycle, which can be targeted in the design of uncompetitive inhibitors as potential anti‐mycobacterial agents, or as chemical genetic probes of function. © Proteins 2013. © 2012 Wiley Periodicals, Inc.  相似文献   
96.
Abstract

Mycobacterium tuberculosis (Mt) is a leading cause of infectious disease in the world today. This outlook is aggravated by a growing number of Mt infections in individuals who are immunocompromised as a result of HIV infections. Thus, new and more potent anti-tuberculosis agents are necessary. Therefore, DNA gyrase was selected as a target enzyme to combat Mt. In this work, the first three-dimensional molecular model of the hypothetical structures for the Mycobacterium tuberculosis DNA gyrase (mtDNAg) was elucidated by a homology modeling method. In addition, the orientations and binding affinities of some gatifloxacin analogs with those new structures were investigated. Our findings could be helpful for the design of new more potent gatifloxacin analogs.  相似文献   
97.
98.
The increasing clinical importance of drug-resistant mycobacterial pathogens has lent additional urgency to microbiological research and new antimycobacterial compound development. For this purpose, new triazoles were synthesized and evaluated for antituberculosis activity. A series of 4-arylidenamino-4H-1,2,4-triazole-3-thiol derivatives (2a–n) were synthesized from the treatment of 4-amino-4H-1,2,4-triazoles-3-thiol (1) with the respective aldehydes and were evaluated for antituberculosis activity against Mycobacterium tuberculosis H37Rv (ATCC 27294), using the BACTEC 460 radiometric system and BACTEC 12B medium. Compound 2k showed an intereting activity at 6.25 μg/mL with a 87 percentage inhibition.  相似文献   
99.
In this study, a series of novel 3-(substituted phenyl)-6,7-dimethoxy-3a,4-dihydro-3H-indeno[1,2-c]isoxazole analogues were synthesized and evaluated for antimycobacterial activity against Mycobacterium tuberculosis (MTB) H37Rv and isoniazid resistant M. tuberculosis (INHR-MTB). All the newly synthesized compounds were showing moderate to high inhibitory activities. The compound 6,7-dimethoxy-3-(4-chloro phenyl)-4H-indeno[1,2-c]isoxazole (4b) was found to be the most promising compound, active against MTB H37Rv and INHR-MTB with minimum inhibitory concentrations of 0.22 and 0.34 μM.  相似文献   
100.
A series of halogenated sulfanilamides and halogenated benzolamide derivatives have been investigated as inhibitors of three β-carbonic anhydrases (CAs, EC 4.2.1.1) from the bacterial pathogen Mycobacterium tuberculosis, mtCA 1 (Rv1284), mtCA 2 (Rv3588c) and mtCA 3 (Rv3273). All three enzymes were inhibited with efficacies between the submicromolar to the micromolar one, depending on the substitution pattern at the sulfanilamide moiety/fragment of the molecule. Best inhibitors were the halogenated benzolamides (KIs in the range of 0.12–0.45 μM) whereas the halogenated sulfanilamides were slightly less inhibitory (KIs in the range of 0.41–4.74 μM). This class of β-CA inhibitors may have the potential for developing antimycobacterial agents with a diverse mechanism of action compared to the clinically used drugs for which many strains exhibit multi-drug/extensive multi-drug resistance.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号